MedTrace Logo

Phase 1 Study of Anti-glycation Agent GLY-230 in Healthy Subjects

NCT00544921 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2016-02-10

No results posted yet for this study

Summary

To test the safety of GLY-230 and to evaluate how long drug stays in blood after taking it by mouth.

Conditions

Interventions

DRUG

GLY-230

OTHER

Placebo

No drug administered

Sponsors & Collaborators

  • University of Florida

    collaborator OTHER

  • Glycadia

    lead INDUSTRY

Principal Investigators

  • Laurence Kennedy · Univ. FLA Gainesville

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2006-10-31
Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00544921 on ClinicalTrials.gov